Loading...
menu
Search
Features
Markets
News
Resources
Pricing
Home
ETF
RNAZ
RNAZ
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
Latest RNAZ ETF News Today | Earnings, Events & Price Alerts
RNAZ News
TransCode Enters Exclusive License Agreement with Unleash Immuno Oncolytics
1d ago
PRnewswire
TransCode Publishes Novel Tumor Immunotherapy Research
Feb 23 2026
PRnewswire
TransCode Publishes TTX-MC138 Research for Glioblastoma Treatment
Jan 06 2026
PRnewswire
TransCode's TTX-MC138 Significantly Extends Survival in Glioblastoma Mouse Models
Jan 06 2026
Newsfilter
TransCode Appoints Jack E. Stover to Board of Directors, Enhancing Leadership Experience
Dec 22 2025
PRnewswire
TransCode Appoints Jack E. Stover to Board, Enhancing Oncology Expertise
Dec 22 2025
Newsfilter
TransCode's TTX-MC138 Set to Begin Phase 2a Trial Within Quantum Leap PRE-I-SPY Initiative
Dec 12 2025
NASDAQ.COM
TransCode Partners with Quantum Leap for TTX-MC138 Phase 2a Clinical Trial
Dec 11 2025
Newsfilter
TransCode Therapeutics Expands Executive Team with Appointment of Dr. Michel Janicot as Senior Development Officer
Nov 17 2025
PRnewswire
TransCode Purchases Polynoma from CK Life Sciences
Oct 08 2025
NASDAQ.COM
TransCode Therapeutics (RNAZ) announces the acquisition of Polynoma and a $25 Million strategic financing by a subsidiary of CK Life Sciences to form a first-in-class unique immuno-oncology and metastatic prevention oncology company
Oct 08 2025
PRnewswire
FedEx Shares Rise 5%; Check Out 20 Stocks Making Moves in Premarket Trading
Sep 19 2025
Benzinga
TransCode Therapeutics Appoints Dr. Phillip D. Zamore to Science Advisory Board
May 28 2025
PRnewswire
Upcoming Stock Splits This Week (May 12 to May 16) – Stay Invested
May 11 2025
TipRanks
TransCode Therapeutics Successfully Completes Initial Dosing of Patients in Cohort 4 of Phase 1a Clinical Trial; No Dose Limiting Toxicities Reported
May 08 2025
Newsfilter
TransCode Therapeutics Announces Effective Date for 1-for-28 Reverse Stock Split
May 05 2025
Newsfilter
Show More News
